This outcome underscores the efficacy of MSCsanti-CD33-anti-CD3 as a vehicle for localized and sustained production and delivery of anti-CD33-anti-CD3 bi-specific antibodies, providing a promising strategy for targeted T cell-based immunotherapy for AML [39]. The gene discussed is CD33; the disease is acute myeloid leukemia.